Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults aged 60-64; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Pfizer multivalent pneumococcal conjugate vaccine (unofficial name from sponsor)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-12-26